17 alpha-Hydroxyprogesterone Caproate clinical trials
Also written Makena, 17P and Proluton depot.
How each study uses 17 alpha-Hydroxyprogesterone Caproate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the 17 alpha-Hydroxyprogesterone Caproate studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 26 Dec 1974 · HYDROXYPROGESTERONE CAPROATE · NDA 017439 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
20 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2004 | 2 |
| 2006 | 2 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2013 | 1 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 14
AMAG Pharmaceuticals, Inc. (3) · Assiut University (2) · The George Washington University Biostatistics Center (2) · Obstetrix Medical Group (2) · Aswan University Hospital (2) · University of South Florida (1) · University of North Carolina, Chapel Hill (1) · University of Modena and Reggio Emilia (1)
Often tested with
Tested in the same studies.
Progesterone (3) · Nafarelin (1) · Estradiol, estriol drug combination (1) · Utrogestan (1)
Related medicines
As reviewed, each with the page that says it.
- One of Progestins source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test 17 alpha-Hydroxyprogesterone Caproate.
- Jan 2027Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed PreeclampsiaPhase 2 · University of Mississippi Medical Center
Studies
Open first, then newest update. How each study uses 17 alpha-Hydroxyprogesterone Caproate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 20
- Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed PreeclampsiaRecruitingPhase 2University of Mississippi Medical CenterNCT02989025Written as 17 OHPC
- Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm DeliveryCompletedPhase 3AMAG Pharmaceuticals, Inc.NCT01004029Written as Hydroxyprogesterone Caproate Injection (HPC), 250mg/mL
- Progesterone in Expectantly Managed Early-onset PreeclampsiaCompletedPhase 4Assiut UniversityNCT04077853Written as 17 Hydroxyprogesterone Capronate
- Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal WomenCompletedPhase 1AMAG Pharmaceuticals, Inc.NCT02940522Written as Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
- Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal WomenTerminatedPhase 3AMAG Pharmaceuticals, Inc.NCT02937766Written as Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
- 17OHP-C Dosing Among Obese Pregnant WomenCompletedPhase 3University of South FloridaNCT03433040Written as 17-Hydroxyprogesterone Capronate
- Improving Pregnancy Outcomes With ProgesteroneCompletedPhase 3University of North Carolina, Chapel HillNCT03297216Written as 17P
- Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High RespondersStatus unknownPhase 4Assaf-Harofeh Medical CenterNCT04797338Written as Hydroxyprogesterone Caproate
- RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short CervixTerminatedPhase 3The George Washington University Biostatistics CenterNCT00439374Written as 17 alpha-hydroxyprogesterone caproate
- Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS)CompletedPhase 3The George Washington University Biostatistics CenterNCT00099164Written as 17 alpha-hydroxyprogesterone caproate (17P)
- 17-Alpha-Hydroxyprogesterone Caproate in Pregnant Women With Placenta PreviaStatus unknownNot applicableAswan University HospitalNCT03779438Written as 17-OHPC
- Vaginal Progesterone Versus 17-Alpha-Hydroxyprogesterone Caproate in Placenta PreviaStatus unknownNot applicableAswan University HospitalNCT03779451Written as 17-OHPC
- Intramuscular Hydroxyprogesterone Caproate and Placenta PreviaCompletedPhase 2Assiut UniversityNCT03130504Written as 17α hydroxy progesterone caproate
- Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)CompletedPhase 2/3Obstetrix Medical GroupNCT01119963Written as 17-alpha-hydroxy-progesterone caproate, Makena®
- Progestagens for the Tertiary Prophylaxis of Preterm DeliveryCompletedPhase 3University of Modena and Reggio EmiliaNCT01178788Written as 17 alpha-hydroxy progesterone caproate
- 17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet PregnanciesCompletedPhase 2/3Obstetrix Medical GroupNCT00163020Written as 17-alpha-hydroxyprogesterone caproate injectable
- Study of Pharmacology of 17-OHPC in PregnancyCompletedPhase 2University of PittsburghNCT00409825Written as 17-OHPC
- Prevention of Preterm Labor in Patients With a Previous Episode of Threatened Preterm Labor With ProgesteroneStatus unknownPhase 3Saint Thomas Hospital, PanamaNCT01317225Written as 17 α hydroxyprogesterone caproate
- Pharmacokinetic Study of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) and Its Metabolites in BloodCompletedPhase 1Lumara Health, Inc.NCT01899846Written as Hydroxyprogesterone caproate 250 mg/ml
- Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone CaproateCompletedPhase 2American University of Beirut Medical CenterNCT00141908Written as 17-alpha Hydroxyprogesterone Caproate
Codes
What other systems call 17 alpha-Hydroxyprogesterone Caproate · ClinicalTrials.gg INT006787
- MeSH (NLM) D00007771317 alpha-Hydroxyprogesterone CaproateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 276F2O42F5HYDROXYPROGESTERONE CAPROATEConfirmed FDA, NLM, Wikidata
- RxNorm 12488Confirmed FDA, Wikidata
- Wikidata Q3792032hydroxyprogesterone caproateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C960Hydroxyprogesterone CaproateOne source FDA
- DrugBank DB06789One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077713 | 17 alpha-Hydroxyprogesterone Caproate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 276F2O42F5 | HYDROXYPROGESTERONE CAPROATE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 12488 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3792032 | hydroxyprogesterone caproate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C960 | Hydroxyprogesterone Caproate | One source FDA |
| DrugBank | DB06789 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.